Skip to main content
KURA
NASDAQ Life Sciences

Kura Oncology Reports First Product Revenue for KOMZIFTI™ Following FDA Approval, Details Robust Pipeline Expansion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.07
Mkt Cap
$744M
52W Low
$5.41
52W High
$12.49
52W Position info
49% above low
Off High info
35% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

KURA sits 49% above its 52-week low of $5.41.

Summary

Kura Oncology's 2025 annual report details the FDA approval and commercial launch of its first product, KOMZIFTI™, alongside a significant net loss and continued investment in a broad oncology pipeline.


Key Events · Product Development and Regulatory · KURA

  • FDA Approval and Commercial Launch of KOMZIFTI™

    Kura Oncology received FDA approval for KOMZIFTI™ (ziftomenib) on November 13, 2025, for relapsed or refractory NPM1-mutated AML, initiating commercial sales on November 21, 2025. This marks the company's transition to a commercial-stage organization.

  • First Product Revenue Reported

    The company reported its first product revenue of $2.1 million for the year ended December 31, 2025, primarily from KOMZIFTI™ sales in the United States.

  • Significant Net Loss and Increased Expenses

    Kura Oncology reported a net loss of $278.7 million for 2025, an increase from $174.0 million in 2024, driven by substantial increases in research and development expenses ($251.1 million) and selling, general and administrative expenses ($120.0 million) to support pipeline and commercialization efforts.

  • Strong Cash Position and Runway

    As of December 31, 2025, the company held $667.2 million in cash, cash equivalents, and short-term investments, which, combined with anticipated collaboration payments, is expected to fund operations into the fourth quarter of 2027.


Analysis · KURA · Life Sciences

Kura Oncology's 2025 annual report highlights a pivotal year marked by the FDA approval and commercial launch of its first product, KOMZIFTI™ (ziftomenib), for relapsed or refractory NPM1-mutated AML. This transition to a commercial-stage company is a significant de-risking event, supported by strong market access and inclusion in NCCN guidelines. While the company reported a substantial net loss of $278.7 million, this is typical for a biotech investing heavily in R&D and commercialization. The robust pipeline, including ziftomenib in combination therapies and other candidates, along with a solid cash runway into Q4 2027, positions the company for future growth. Investors should monitor the uptake of KOMZIFTI™ and continued progress in its expanded clinical programs.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KURA was trading at $8.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $744M. The 52-week trading range was $5.41 to $12.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KURA - Latest Insights

KURA
Nov 16, 2026, 7:45 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $7.15
Real-time Price: $7.40 info
Change: +$0.250 (+3%) info
Market Cap: $674.39M info
KURA
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.29
Real-time Price: $7.40 info
Change: +$0.110 (+2%) info
Market Cap: $674.39M info
KURA
Nov 10, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.20
Real-time Price: $7.40 info
Change: +$0.200 (+3%) info
Market Cap: $674.39M info
KURA
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $7.40 info
Change: -$0.050 (-0.67%) info
Market Cap: $674.39M info
KURA
Nov 10, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.45
Real-time Price: $7.40 info
Change: -$0.050 (-0.67%) info
Market Cap: $674.39M info